SG11201606054SA - Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use - Google Patents

Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use

Info

Publication number
SG11201606054SA
SG11201606054SA SG11201606054SA SG11201606054SA SG11201606054SA SG 11201606054S A SG11201606054S A SG 11201606054SA SG 11201606054S A SG11201606054S A SG 11201606054SA SG 11201606054S A SG11201606054S A SG 11201606054SA SG 11201606054S A SG11201606054S A SG 11201606054SA
Authority
SG
Singapore
Prior art keywords
methylcyclohexylamino
butylamino
carboxamide
pyrimidine
tert
Prior art date
Application number
SG11201606054SA
Inventor
Antonio Christian Ferretti
Hon-Wah Man
Jale Muslehiddinoglu
Jean Xu
Kelvin Hin-Yeong Yong
Marie Georges Beauchamps
Mohit Atul Kothare
Nanfei Zhou
Nathan Andrew Boersen
Ying Li
Robert Hilgraf
Mark A Nagy
Daozhong Zou
Lianfeng Huang
Original Assignee
Signal Pharm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53678405&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201606054S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Signal Pharm Llc filed Critical Signal Pharm Llc
Publication of SG11201606054SA publication Critical patent/SG11201606054SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
SG11201606054SA 2014-01-30 2015-01-29 Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use SG11201606054SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461933636P 2014-01-30 2014-01-30
US201462025161P 2014-07-16 2014-07-16
PCT/US2015/013412 WO2015116755A2 (en) 2014-01-30 2015-01-29 Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use

Publications (1)

Publication Number Publication Date
SG11201606054SA true SG11201606054SA (en) 2016-08-30

Family

ID=53678405

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201606054SA SG11201606054SA (en) 2014-01-30 2015-01-29 Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use

Country Status (31)

Country Link
US (6) US9365524B2 (en)
EP (2) EP3099302B1 (en)
JP (3) JP2017504632A (en)
KR (2) KR20220051440A (en)
CN (3) CN113717110A (en)
AU (2) AU2015211036B2 (en)
BR (2) BR122020003206B1 (en)
CA (1) CA2938187C (en)
CL (1) CL2016001927A1 (en)
CR (1) CR20160346A (en)
CY (1) CY1123267T1 (en)
DK (1) DK3099302T3 (en)
EA (2) EA031671B1 (en)
ES (1) ES2811834T3 (en)
HR (1) HRP20201244T1 (en)
HU (1) HUE051266T2 (en)
IL (2) IL246931B (en)
LT (1) LT3099302T (en)
MX (3) MX2016009989A (en)
MY (1) MY180020A (en)
NZ (3) NZ715903A (en)
PE (1) PE20161437A1 (en)
PH (1) PH12016501472A1 (en)
PL (1) PL3099302T3 (en)
PT (1) PT3099302T (en)
RS (1) RS60715B1 (en)
SA (1) SA516371578B1 (en)
SG (1) SG11201606054SA (en)
SI (1) SI3099302T1 (en)
TW (1) TWI631108B (en)
WO (1) WO2015116755A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2697712C2 (en) 2011-04-22 2019-08-19 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Substituted diaminocarboxamide and diaminocarbonitrile derivatives of pyrimidines, compositions thereof and methods of treating use thereof
NZ715903A (en) * 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
ES2882954T3 (en) 2014-12-16 2021-12-03 Signal Pharm Llc Medical uses comprising methods for the measurement of inhibition of c-Jun N-terminal kinase in the skin
AU2015362728B2 (en) 2014-12-16 2020-06-25 Signal Pharmaceuticals, Llc Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
EP3250557A4 (en) 2015-01-29 2018-06-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
WO2017019487A1 (en) 2015-07-24 2017-02-02 Celgene Corporation Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein
CN111934089B (en) 2019-05-13 2021-10-26 华为技术有限公司 Antenna device and mobile terminal

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH549339A (en) 1971-05-12 1974-05-31 Ciba Geigy Ag HERBICIDAL AGENT.
US5811428A (en) * 1995-12-18 1998-09-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions
US5852028A (en) * 1995-12-18 1998-12-22 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
US5935966A (en) * 1995-09-01 1999-08-10 Signal Pharmaceuticals, Inc. Pyrimidine carboxylates and related compounds and methods for treating inflammatory conditions
EP1054004B1 (en) 1997-12-15 2008-07-16 Astellas Pharma Inc. Novel pyrimidine-5-carboxamide derivatives
ES2274634T3 (en) 1998-08-29 2007-05-16 Astrazeneca Ab PIRIMIDINE COMPOUNDS.
AU5107900A (en) 1999-06-09 2000-12-28 Yamanouchi Pharmaceutical Co., Ltd. Novel heterocyclic carboxamide derivatives
AU5108000A (en) 1999-06-10 2001-01-02 Yamanouchi Pharmaceutical Co., Ltd. Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
US7429599B2 (en) * 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
US7129242B2 (en) * 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US7122544B2 (en) * 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
AU2003220968A1 (en) 2002-03-28 2003-10-13 Kyowa Hakko Kogyo Co., Ltd. Anti-inflammatory agent
US7449456B2 (en) * 2002-06-28 2008-11-11 Astellas Pharma, Inc. Diaminopyrimidinecarboxamide derivative
BR0313059B8 (en) 2002-07-29 2021-07-27 Rigel Pharmaceuticals compound, and, pharmaceutical composition
AU2003293409A1 (en) * 2002-12-09 2004-06-30 Karl K. Johe Method for discovering neurogenic agents
WO2004054617A1 (en) 2002-12-13 2004-07-01 Kyowa Hakko Kogyo Co., Ltd. Preventives and/or remedies for central diseases
US20040242613A1 (en) 2003-01-30 2004-12-02 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of PKC-theta
PL1660458T3 (en) 2003-08-15 2012-07-31 Novartis Ag 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
CN1871009A (en) 2003-09-24 2006-11-29 惠氏控股公司 5-arylpyrimidines as anticancer agents
WO2005095382A1 (en) 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. Anti-tumor agent
JP2008505910A (en) 2004-07-08 2008-02-28 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Pyrimidine derivatives useful as inhibitors of PKC-theta
AU2005281735A1 (en) 2004-09-10 2006-03-16 Nycomed Gmbh Ciclesonide and syk inhibitor combination and methods of use thereof
EP1791538A1 (en) 2004-09-10 2007-06-06 Altana Pharma AG Roflumilast and syk inhibitor combination and methods of use thereof
CA2575472C (en) 2004-09-30 2013-07-30 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-substituted pyrimidines
JP2006124387A (en) 2004-09-30 2006-05-18 Taisho Pharmaceut Co Ltd New quinoline, tetrahydroquinazoline, and pyrimidine derivative, and treating method associated with their use
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
US20110098301A1 (en) 2005-03-10 2011-04-28 Bayer Healthcare Llc Pyrimidine Derivatives for Treatment of Hyperproliferative Disorders
DE102005062742A1 (en) * 2005-12-22 2007-06-28 Bayer Schering Pharma Ag New sulfoximine-substituted pyrimidines useful for treating e.g. diseases caused by inflammatory, allergic or proliferative processes, oncological diseases, cancer, eye, autoimmune and neurodegerative diseases
CA2657260A1 (en) 2006-07-21 2008-01-24 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors
US20080139531A1 (en) 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
CN103951658B (en) 2007-04-18 2017-10-13 辉瑞产品公司 Sulfamide derivative for treating abnormal cell growth
WO2008132505A1 (en) 2007-04-27 2008-11-06 Astrazeneca Ab N' - (phenyl) -n- (morpholin-4-yl-pyridin-2-yl) -pyrimidine-2, 4-diamine derivatives as ephb4 kinase inhibitors for the treatment of proliferative conditions
MX2010000658A (en) 2007-07-16 2010-03-26 Astrazeneca Ab Pyrimidine derivatives 934.
AU2008275918B2 (en) 2007-07-17 2014-01-30 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as PKC inhibitors
CA2728893C (en) 2008-04-16 2017-03-14 Portola Pharmaceuticals, Inc. Inhibitors of syk protein kinase
CA2960692C (en) * 2008-04-16 2019-09-24 Portola Pharmaceuticals, Inc. 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinase inhibitors
CA2723185A1 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
EA029131B1 (en) 2008-05-21 2018-02-28 Ариад Фармасьютикалз, Инк. Phosphorous derivatives as kinase inhibitors
PE20100087A1 (en) 2008-06-25 2010-02-08 Irm Llc COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
KR20110025224A (en) 2008-06-27 2011-03-09 아빌라 테라퓨틱스, 인크. Heteroaryl compounds and uses thereof
CA2735730A1 (en) 2008-09-01 2010-03-04 Astellas Pharma Inc. 2,4-diaminopyrimidine compound
JP2012502882A (en) 2008-09-18 2012-02-02 アステラス製薬株式会社 Heterocyclic carboxamide compounds
WO2010038081A2 (en) 2008-10-03 2010-04-08 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
CN107904201B (en) 2008-10-31 2021-11-16 詹森生物科技公司 Differentiation of human embryonic stem cells into the pancreatic endocrine lineage
US8809538B2 (en) 2009-01-12 2014-08-19 Array Biopharma Inc. Piperidine-containing compounds and use thereof
BRPI1006162A2 (en) * 2009-01-13 2019-09-24 Glaxo Group Ltd "compound, process for preparing a compound, pharmaceutical formulation, and use of a compound".
CA2749837C (en) 2009-01-21 2017-07-11 Rigel Pharmaceuticals, Inc. Derivatives of n2-(3-pyridil or phenyl)-n4-(4-piperidyl)-2,4-pyrimidinediamine useful in the treatment of inflammatory, autoimmune or proliferative diseases
US8367689B2 (en) * 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
TWI484961B (en) * 2009-05-08 2015-05-21 Astellas Pharma Inc Diamine heterocyclic methyl ester compounds
MX2011013325A (en) 2009-06-10 2012-04-30 Abbott Lab 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors.
JP2012197231A (en) 2009-08-06 2012-10-18 Oncotherapy Science Ltd Pyridine and pyrimidine derivative having ttk-inhibiting action
WO2011065800A2 (en) 2009-11-30 2011-06-03 주식회사 오스코텍 Pyrimidine derivative, method for preparing same and pharmaceutical composition containing same
CA2780759A1 (en) * 2009-12-01 2011-06-09 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
WO2012012619A1 (en) 2010-07-21 2012-01-26 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
US8580805B2 (en) * 2010-08-31 2013-11-12 Hubert Maehr Pyrimidine carboxamide derivatives
WO2012044936A1 (en) 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
US20130237493A1 (en) 2010-09-30 2013-09-12 Portola Pharmaceuticals, Inc. Combination therapy of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine
RU2697712C2 (en) * 2011-04-22 2019-08-19 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Substituted diaminocarboxamide and diaminocarbonitrile derivatives of pyrimidines, compositions thereof and methods of treating use thereof
US9321763B2 (en) * 2012-04-04 2016-04-26 Rigel Pharmaceuticals, Inc. Protein kinase C inhibitors and uses thereof
CA2892677A1 (en) * 2012-12-04 2014-06-12 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
WO2014151900A1 (en) * 2013-03-14 2014-09-25 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
CN104262328B (en) * 2013-09-18 2016-09-07 北京韩美药品有限公司 The compound of suppression BTK and/or JAK3 kinase activity
CN106170290A (en) * 2013-12-20 2016-11-30 西格诺药品有限公司 Substituted di-amino-pyrimidine based compound, combinations thereof and treatment method thereof
NZ715903A (en) * 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
AU2015362728B2 (en) * 2014-12-16 2020-06-25 Signal Pharmaceuticals, Llc Formulations of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
EP3250557A4 (en) * 2015-01-29 2018-06-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide

Also Published As

Publication number Publication date
KR102505677B1 (en) 2023-03-03
KR20220051440A (en) 2022-04-26
CN113717109A (en) 2021-11-30
PH12016501472B1 (en) 2016-08-22
HUE051266T2 (en) 2021-03-01
ES2811834T3 (en) 2021-03-15
US10226461B2 (en) 2019-03-12
CY1123267T1 (en) 2021-12-31
BR122020003206B1 (en) 2023-02-07
BR112016017776A2 (en) 2017-08-08
KR20160113269A (en) 2016-09-28
AU2015211036B2 (en) 2020-05-21
NZ629885A (en) 2016-04-29
MX2020003173A (en) 2022-03-30
JP2017504632A (en) 2017-02-09
EA036964B1 (en) 2021-01-20
WO2015116755A3 (en) 2015-11-12
JP7317768B2 (en) 2023-07-31
IL246931A0 (en) 2016-09-29
SA516371578B1 (en) 2019-09-01
CR20160346A (en) 2016-11-23
US10517873B2 (en) 2019-12-31
MX2016009989A (en) 2017-02-20
US20150210650A1 (en) 2015-07-30
US20180028534A1 (en) 2018-02-01
US9365524B2 (en) 2016-06-14
EA201691544A1 (en) 2017-01-30
US20220378785A1 (en) 2022-12-01
PL3099302T3 (en) 2021-03-08
SI3099302T1 (en) 2020-10-30
NZ761068A (en) 2023-02-24
LT3099302T (en) 2020-09-10
CA2938187A1 (en) 2015-08-06
RS60715B1 (en) 2020-09-30
US9814713B2 (en) 2017-11-14
CA2938187C (en) 2022-08-09
EP3738954A1 (en) 2020-11-18
CN113717110A (en) 2021-11-30
AU2020202146A1 (en) 2020-04-16
JP2019142893A (en) 2019-08-29
PH12016501472A1 (en) 2016-08-22
IL275305B (en) 2021-12-01
EP3099302B1 (en) 2020-06-17
CL2016001927A1 (en) 2017-02-24
WO2015116755A8 (en) 2016-09-22
US20190167678A1 (en) 2019-06-06
PE20161437A1 (en) 2017-01-07
JP2020183437A (en) 2020-11-12
MY180020A (en) 2020-11-19
IL246931B (en) 2020-06-30
HRP20201244T1 (en) 2020-11-13
TWI631108B (en) 2018-08-01
TW201615627A (en) 2016-05-01
CN106163523A (en) 2016-11-23
IL275305A (en) 2020-07-30
PT3099302T (en) 2020-08-27
AU2015211036A1 (en) 2016-08-11
EP3099302A2 (en) 2016-12-07
AU2020202146B2 (en) 2021-11-18
US20200078359A1 (en) 2020-03-12
JP6742466B2 (en) 2020-08-19
WO2015116755A2 (en) 2015-08-06
MX2019005715A (en) 2019-08-12
US11241430B2 (en) 2022-02-08
US20160256459A1 (en) 2016-09-08
NZ715903A (en) 2017-06-30
BR112016017776A8 (en) 2020-06-30
EA031671B1 (en) 2019-02-28
EP3099302A4 (en) 2017-10-04
NZ722412A (en) 2022-10-28
EA201792281A1 (en) 2018-03-30
DK3099302T3 (en) 2020-08-24

Similar Documents

Publication Publication Date Title
HK1247238B (en) Engineered crispr-cas9 compositions and methods of use
HK1254525A1 (en) Therapeutic compositions, combinations, and methods of use
IL252900B (en) Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
IL275305B (en) Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
IL259246A (en) Compositions of therapeutic substances, methods and uses thereof
HK1259372A1 (en) Therapeutic compounds, compositions and methods of use thereof
HUE056172T2 (en) Compositions of selenoorganic compounds and methods of use thereof
IL277814A (en) Eutectic formulations of cyclobenzaprine hydrochloride and methods of producing same
HK1254822A1 (en) Compositions and methods for decreasing tau expression
EP3250557A4 (en) Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
ZA201801214B (en) Compositions and methods for treatment of stroke and other cns disorders
HK1252057A1 (en) Novel method of use and compositions
HK1258765A1 (en) Therapeutic compounds, compositions and methods of use thereof
ZA201704927B (en) Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide,compositions thereof and methods of their use
IL247645A0 (en) Compositions of selenoorganic compounds and methods of use thereof
EP3280406A4 (en) Compositions and methods for treatment of movement disorders